UA116215C2 - Спосіб лікування або полегшення плоского фолікулярного лишаю - Google Patents

Спосіб лікування або полегшення плоского фолікулярного лишаю

Info

Publication number
UA116215C2
UA116215C2 UAA201503407A UAA201503407A UA116215C2 UA 116215 C2 UA116215 C2 UA 116215C2 UA A201503407 A UAA201503407 A UA A201503407A UA A201503407 A UAA201503407 A UA A201503407A UA 116215 C2 UA116215 C2 UA 116215C2
Authority
UA
Ukraine
Prior art keywords
methods
pharmaceutically acceptable
patient
related conditions
treating hair
Prior art date
Application number
UAA201503407A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джаммарія Джуліані
Ральф Паус
Ювал Рамот
Серджо Бароні
Франческа Віті
Сальваторе Беллінвія
Барбара Марзані
Original Assignee
Ногра Фарма Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ногра Фарма Лімітед filed Critical Ногра Фарма Лімітед
Publication of UA116215C2 publication Critical patent/UA116215C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
UAA201503407A 2012-09-13 2013-09-13 Спосіб лікування або полегшення плоского фолікулярного лишаю UA116215C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261700623P 2012-09-13 2012-09-13
PCT/EP2013/069062 WO2014041140A1 (en) 2012-09-13 2013-09-13 Methods of treating hair related conditions

Publications (1)

Publication Number Publication Date
UA116215C2 true UA116215C2 (uk) 2018-02-26

Family

ID=49170707

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201503407A UA116215C2 (uk) 2012-09-13 2013-09-13 Спосіб лікування або полегшення плоского фолікулярного лишаю

Country Status (25)

Country Link
US (2) US20150250749A1 (enExample)
EP (1) EP2895160B1 (enExample)
JP (1) JP2015528479A (enExample)
KR (1) KR20150054934A (enExample)
CN (1) CN104837486A (enExample)
AU (1) AU2013314288B2 (enExample)
BR (1) BR112015005467A2 (enExample)
CA (1) CA2883823A1 (enExample)
CY (1) CY1120793T1 (enExample)
DK (1) DK2895160T3 (enExample)
EA (1) EA035986B1 (enExample)
ES (1) ES2675169T3 (enExample)
HR (1) HRP20181000T1 (enExample)
HU (1) HUE037903T2 (enExample)
IL (1) IL237449A0 (enExample)
IN (1) IN2015DN02104A (enExample)
LT (1) LT2895160T (enExample)
MX (1) MX356888B (enExample)
NZ (1) NZ705389A (enExample)
PL (1) PL2895160T3 (enExample)
PT (1) PT2895160T (enExample)
SI (1) SI2895160T1 (enExample)
TR (1) TR201809219T4 (enExample)
UA (1) UA116215C2 (enExample)
WO (1) WO2014041140A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
EA020856B1 (ru) 2009-02-16 2015-02-27 Джулиани Интернэшнл Лимитед Способы лечения патологических состояний, связанных с волосами
JP6301844B2 (ja) 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
EP2844242A1 (en) 2012-04-18 2015-03-11 Nogra Pharma Limited Methods of treating lactose intolerance
EP3921299B1 (en) * 2019-02-08 2024-11-20 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
WO2025132838A1 (en) * 2023-12-20 2025-06-26 Nogra Pharma Limited Acne topical formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020856B1 (ru) * 2009-02-16 2015-02-27 Джулиани Интернэшнл Лимитед Способы лечения патологических состояний, связанных с волосами
EP2844242A1 (en) * 2012-04-18 2015-03-11 Nogra Pharma Limited Methods of treating lactose intolerance

Also Published As

Publication number Publication date
EA201590546A1 (ru) 2015-08-31
LT2895160T (lt) 2018-07-10
JP2015528479A (ja) 2015-09-28
IN2015DN02104A (enExample) 2015-08-14
MX2015003278A (es) 2015-07-06
TR201809219T4 (tr) 2018-07-23
WO2014041140A1 (en) 2014-03-20
IL237449A0 (en) 2015-04-30
SI2895160T1 (sl) 2018-09-28
PT2895160T (pt) 2018-06-29
CA2883823A1 (en) 2014-03-20
AU2013314288B2 (en) 2018-07-05
US20210113505A1 (en) 2021-04-22
CN104837486A (zh) 2015-08-12
US20150250749A1 (en) 2015-09-10
KR20150054934A (ko) 2015-05-20
MX356888B (es) 2018-06-18
EP2895160A1 (en) 2015-07-22
CY1120793T1 (el) 2020-05-29
AU2013314288A1 (en) 2015-03-19
HRP20181000T1 (hr) 2018-09-21
NZ705389A (en) 2018-08-31
HUE037903T2 (hu) 2018-09-28
ES2675169T3 (es) 2018-07-09
PL2895160T3 (pl) 2018-09-28
DK2895160T3 (en) 2018-06-25
BR112015005467A2 (pt) 2017-07-04
EA035986B1 (ru) 2020-09-09
EP2895160B1 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
MX356888B (es) Metodos para tratar condiciones relacionadas con el cabello.
PH12013501427B1 (en) Melanin modification compositions and methods of use
IN2014DN09434A (enExample)
NZ726488A (en) Compositions and methods for transmucosal absorption
MX2015008187A (es) Inhibidores de alk deuterados.
IN2014MN01755A (enExample)
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
IN2015DN01728A (enExample)
MX2015003021A (es) Derivados de acido glicirretinico y metodos de uso de los mismos.
IN2015DN01119A (enExample)
MX369717B (es) Derivados de benzamidas que inhiben el receptor de p2x7 y el uso de dichos compuestos en el tratamiento de dolor, inflamación, trastornos neurológicos o neuropsiquiátricos.
WO2013006336A3 (en) Methods and compositions useful for treating fitzpatrick type iv, v or vi skin
PH12013500738A1 (en) Brimonidine gel compositions and methods of use
WO2011117377A3 (en) Compositions comprising brimonidine for the treatment of erythema
WO2012161497A3 (ko) 보습능이 우수한 펩타이드 유도체 및 이의 용도
BR112012015984A2 (pt) composição para melhorar a função cerebral, e, polipeptídeo
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
GB201115977D0 (en) Neurodevelopmental disorders
PH12015500282A1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
WO2014182653A8 (en) Use of lappaol f to inhibit tumor cell growth